James M Parks

Title: Inventor Spotlight: James M Parks

Introduction:

James M Parks, a talented inventor based in Newark, DE, has made significant contributions to the field of pharmaceuticals with his innovative patents. With a total of 2 patents to his name, Parks is recognized for his groundbreaking work in the development of JAK inhibitors.

Latest Patents:

1. Process and intermediates for preparing a JAK inhibitor: Parks' revolutionary process for preparing ruxolitinib, or a salt thereof, has paved the way for advancements in treating various medical conditions. This patent focuses on synthetic intermediates essential for producing the inhibitor.

2. Processes of preparing a JAK1 inhibitor: Another noteworthy patent by Parks involves the preparation of a selective JAK1 inhibitor, specifically 4-[3-(cyanomethyl)-3-(3',5'-dimethyl-1H, 1'H-4,4'-bipyrazol-1-yl)azetidin-1-yl]-2,5-difluoro-N-[(1S)-2,2,2-trifluoro-1-methylethyl]benzamide. This compound shows promise in the field of pharmaceutical research.

Career Highlights:

James M Parks is associated with Incyte Corporation, a leading pharmaceutical company known for its groundbreaking research and development in oncology and other therapeutic areas. Parks' contributions have significantly enhanced the company's portfolio and reinforced its position as a key player in the industry.

Collaborations:

Throughout his career, Parks has collaborated with esteemed professionals in the field, including Jiacheng Zhou and Yongchun Pan. These collaborations have led to synergistic partnerships and the exchange of innovative ideas, driving further advancements in pharmaceutical research.

Conclusion:

Inventor James M Parks' exceptional work in the field of pharmaceuticals, particularly in the development of JAK inhibitors, has solidified his reputation as a pioneering inventor. His patents and collaborations stand as a testament to his dedication to advancing scientific knowledge and improving patient care.